
Allena Pharmaceuticals ALNA
Quartalsbericht 2022-Q2
hinzugefügt 15.08.2022
Allena Pharmaceuticals Abschreibung & Amortisation 2011-2026 | ALNA
Abschreibung & Amortisation Jährlich Allena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 363 K | 166 K | 163 K | 78 K | 73 K | 46 K | 98 K | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 363 K | 46 K | 141 K |
Abschreibung & Amortisation Vierteljährlich Allena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 243 K | 125 K | - | - | 145 K | 65 K | - | 123 K | 83 K | 41 K | - | 121 K | 79 K | 40 K | - | 44 K | 27 K | 19 K | - | 53 K | 34 K | 17 K | - | 31 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 243 K | 17 K | 75.9 K |
Abschreibung & Amortisation anderer Aktien in der Pharmaeinzelhändler
| Name | Abschreibung & Amortisation | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Happiness Biotech Group Limited
HAPP
|
380 K | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
31.6 M | $ 16.87 | -2.49 % | $ 789 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
AstraZeneca PLC
AZN
|
5.73 B | - | - | $ 96.9 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
3.02 M | $ 7.47 | -4.6 % | $ 205 M | ||
|
Athira Pharma
ATHA
|
972 K | - | - | $ 269 M | ||
|
Galera Therapeutics
GRTX
|
20 K | - | -32.59 % | $ 7.61 M | ||
|
AbCellera Biologics
ABCL
|
18.4 M | $ 4.09 | -7.05 % | $ 1.22 B | ||
|
Coherus BioSciences
CHRS
|
1.3 M | $ 1.57 | -3.68 % | $ 184 M | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.63 | 2.52 % | $ 434 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 3.36 | -3.72 % | $ 5.53 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Eton Pharmaceuticals
ETON
|
4.04 M | $ 30.26 | 1.0 % | $ 814 M | ||
|
Exelixis
EXEL
|
29.1 M | $ 50.13 | -1.9 % | $ 13.6 B | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
546 K | $ 0.72 | -1.58 % | $ 32.9 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Esperion Therapeutics
ESPR
|
105 K | $ 3.12 | - | $ 649 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
Fortress Biotech
FBIO
|
403 K | $ 2.41 | 4.78 % | $ 67.2 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
Forte Biosciences
FBRX
|
64 K | $ 23.11 | -3.55 % | $ 299 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 21.32 | -1.16 % | $ 2.71 B | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
1 K | - | 10.36 % | $ 9.8 M |